945 related articles for article (PubMed ID: 11051136)
1. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Gupta AK; Fleckman P; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
[TBL] [Abstract][Full Text] [Related]
2. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States.
Gupta AK; Joseph WS
J Am Podiatr Med Assoc; 2000; 90(10):495-501. PubMed ID: 11107710
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Gupta AK
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
[TBL] [Abstract][Full Text] [Related]
4. Topical and device-based treatments for fungal infections of the toenails.
Foley K; Gupta AK; Versteeg S; Mays R; Villanueva E; John D
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012093. PubMed ID: 31978269
[TBL] [Abstract][Full Text] [Related]
5. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
Brenner MA; Harkless LB; Mendicino RW; Page JC
J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
[TBL] [Abstract][Full Text] [Related]
6. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
[TBL] [Abstract][Full Text] [Related]
7. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn M; Kraemer KT
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
[TBL] [Abstract][Full Text] [Related]
8. Ciclopirox nail lacquer solution 8% in the 21st century.
Gupta AK; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S96-102. PubMed ID: 11051138
[TBL] [Abstract][Full Text] [Related]
9. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.
Zalacain-Vicuña AJ; Nieto C; Picas J; Martínez H; Bermejo R; Corrales A; Campos FF; Igea SA; Otero-Espinar FJ; Briones VG
Mycoses; 2023 Jul; 66(7):566-575. PubMed ID: 36336989
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
Seebacher C; Nietsch KH; Ulbricht HM
Cutis; 2001 Aug; 68(2 Suppl):17-22. PubMed ID: 11665724
[TBL] [Abstract][Full Text] [Related]
12. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
Schalka S; Nunes S; Gomes Neto A
An Bras Dermatol; 2012; 87(1):19-25. PubMed ID: 22481647
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
[TBL] [Abstract][Full Text] [Related]
14. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy.
Friedlander SF; Chan YC; Chan YH; Eichenfield LF
Pediatr Dermatol; 2013; 30(3):316-22. PubMed ID: 23278851
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Schaller M; Sigurgeirsson B; Sarkany M
Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
[TBL] [Abstract][Full Text] [Related]
16. A multicentre, randomised, parallel-group, double-blind, vehicle-controlled and open-label, active-controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis.
Blume-Peytavi U; Tosti A; Falqués M; Tamarit ML; Carreño C; Galván J; Tebbs V
Mycoses; 2022 Apr; 65(4):392-401. PubMed ID: 34752667
[TBL] [Abstract][Full Text] [Related]
17. Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin.
Friedman-Birnbaum R; Cohen A; Shemer A; Bitterman O; Bergman R; Stettendorf S
Int J Dermatol; 1997 Jan; 36(1):67-9. PubMed ID: 9071624
[TBL] [Abstract][Full Text] [Related]
18. Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.
Pollak RA
J Am Podiatr Med Assoc; 2014 Nov; 104(6):568-73. PubMed ID: 25514267
[TBL] [Abstract][Full Text] [Related]
19. Ciclopirox nail lacquer topical solution 8%.
Gupta AK
Skin Therapy Lett; 2000; 6(1):1-5. PubMed ID: 11027420
[TBL] [Abstract][Full Text] [Related]
20. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.
Elewski BE; Rich P; Pollak R; Pariser DM; Watanabe S; Senda H; Ieda C; Smith K; Pillai R; Ramakrishna T; Olin JT
J Am Acad Dermatol; 2013 Apr; 68(4):600-608. PubMed ID: 23177180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
